Facility鈥檚 right medicine for startups
GERMANY’S Boehringer Ingelheim yesterday launched the first phase of its 70-million-euro (US$77 million) biopharma manufacturing site in Zhangjiang High-Tech Park in Shanghai, the first of its kind set up by a multinational pharma company in China.
The facility aims to bolster the manufacturing capability and serve innovative drug startups or companies that are not capable of setting up their own manufacturing plants.
The joint venture with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co is also expected to enhance the competitiveness of China’s biopharma industry.
Boehringer Ingelheim has been selected as one of the first companies to be included in China’s biopharma contract manufacturing organization pilot project that allows domestic and overseas drug companies to outsource their manufacturing and early-phase R&D work to eligible third parties.
The new facility in Shanghai, the company’s fourth after those in Germany, Austria and the United States, is key to improving its global manufacturing network.
- About Us
- |
- Terms of Use
- |
-
RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔$粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.